CN1694720A - 乳铁蛋白组合物和创伤治疗的方法 - Google Patents

乳铁蛋白组合物和创伤治疗的方法 Download PDF

Info

Publication number
CN1694720A
CN1694720A CNA038250683A CN03825068A CN1694720A CN 1694720 A CN1694720 A CN 1694720A CN A038250683 A CNA038250683 A CN A038250683A CN 03825068 A CN03825068 A CN 03825068A CN 1694720 A CN1694720 A CN 1694720A
Authority
CN
China
Prior art keywords
lactoferrin
wound
compositions
polymer
rhlf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038250683A
Other languages
English (en)
Chinese (zh)
Inventor
J·恩格尔迈尔
A·瓦拉德哈查里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Publication of CN1694720A publication Critical patent/CN1694720A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
CNA038250683A 2002-09-16 2003-09-16 乳铁蛋白组合物和创伤治疗的方法 Pending CN1694720A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41098102P 2002-09-16 2002-09-16
US60/410,981 2002-09-16

Publications (1)

Publication Number Publication Date
CN1694720A true CN1694720A (zh) 2005-11-09

Family

ID=31994228

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038250683A Pending CN1694720A (zh) 2002-09-16 2003-09-16 乳铁蛋白组合物和创伤治疗的方法

Country Status (12)

Country Link
US (3) US7524814B2 (enExample)
EP (2) EP1545587B1 (enExample)
JP (1) JP4516844B2 (enExample)
CN (1) CN1694720A (enExample)
AT (1) ATE497778T1 (enExample)
AU (2) AU2003270690B2 (enExample)
CA (1) CA2499014A1 (enExample)
DE (1) DE60335997D1 (enExample)
DK (2) DK1545587T3 (enExample)
ES (1) ES2358645T3 (enExample)
SI (2) SI2298338T1 (enExample)
WO (1) WO2004024180A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442592A (zh) * 2010-12-29 2013-12-11 Mjn美国控股有限责任公司 包含乳铁蛋白的营养组合物在刺激免疫细胞中的用途
CN106139124A (zh) * 2006-07-03 2016-11-23 让-保罗·佩罗丹 抗菌剂组合物及其用途
CN107854737A (zh) * 2011-08-31 2018-03-30 凯希特许有限公司 减压治疗与清创系统以及方法
CN110075054A (zh) * 2019-06-06 2019-08-02 山东天源人乳库科技发展有限公司 一种来源于人乳的人源性生长因子修复制剂及其制备方法
CN116251224A (zh) * 2023-05-16 2023-06-13 江苏正大天创生物工程有限公司 一种乳铁蛋白凝胶敷料及其应用

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
WO2003094952A1 (en) * 2002-05-10 2003-11-20 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
SI2298338T1 (sl) * 2002-09-16 2012-11-30 Agennix Inc Laktoferinski sestavki in postopki za zdravljenjekožnih ran
EP1581243A4 (en) * 2002-12-06 2008-01-02 Agennix Inc ORAL LACTOFERRIN FOR SEPSIS TREATMENT
AU2003296447A1 (en) * 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
AU2005277404A1 (en) * 2004-08-20 2006-03-02 Smithkline Beecham Corporation Methods of healing wounds by administering human IL-18
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US8263105B2 (en) * 2004-12-01 2012-09-11 Tyco Healthcare Group Lp Biomaterial drug delivery and surface modification compositions
ITRM20040638A1 (it) 2004-12-24 2005-03-24 Advance Holdings Ltd Gel piastrinico semisintetico e metodo per la sua preparazione.
US20060240116A1 (en) * 2005-04-22 2006-10-26 David Jolley Bioactive factors in wound healing topical compositions and methods
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007022537A2 (en) * 2005-08-19 2007-02-22 Agennix Incorporated Use of lactoferrin as a chemokine and a chemotactic modulator
US20070059300A1 (en) * 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
AU2006318655B2 (en) * 2005-11-18 2013-03-28 Glanbia Nutritionals (Ireland) Ltd. Compositions for disrupting and inhibiting reconstitution of wound biofilm
US20070179084A1 (en) * 2006-01-30 2007-08-02 Nation Chiao Tung University Process for reducing the concentration of blood glucose in a diabetic patient
DE602006010656D1 (de) * 2006-02-02 2010-01-07 Euro Celtique Sa Hydrogel für Wundbehandlung
EP1993592A4 (en) * 2006-02-21 2011-11-16 Ventria Bioscience COMPOSITIONS WITH LACTOFERRIN AND METHOD FOR USE THAT TO AIM IN THE GROWTH OF SKIN CELLS
GB0616580D0 (en) * 2006-08-21 2006-09-27 Novathera Ltd Composite material
CA2663417A1 (en) 2006-09-13 2008-03-20 Southeastern Medical Technologies, Llc Methods and compositions for sealing and adhering biological tissues and medical uses thereof
US10143694B2 (en) * 2006-10-27 2018-12-04 Matthew H. Kopacki Advanced formulations and therapies for treating hard-to-heal wounds
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
WO2009123720A2 (en) * 2008-04-01 2009-10-08 Southeastern Medical Technologies, Llc Methods and compositions for medical articles produced from proteinaceous compounds
EP2141242A1 (en) * 2008-07-04 2010-01-06 Universität des Saarlandes Synthetic pathway enzymes for the production of Argyrins
US8614189B2 (en) * 2008-09-24 2013-12-24 University Of Connecticut Carbon nanotube composite scaffolds for bone tissue engineering
US20110015587A1 (en) * 2009-07-14 2011-01-20 Tumey David M Irrigation Device and Method Using Same
JP2011020973A (ja) * 2009-07-17 2011-02-03 Nrl Pharma Inc 難治性の皮膚潰瘍治療用の医薬組成物、及び、皮膚潰瘍予防用化粧料
RU2012126140A (ru) * 2009-11-25 2013-12-27 Нестек С.А. Питательные композиции, включающие высокобелковый компонент и экзогенные нуклеотиды
US8545927B2 (en) 2010-05-10 2013-10-01 University Of Connecticut Lactoferrin-based biomaterials for tissue regeneration and drug delivery
IN2013CN00089A (enExample) * 2010-07-01 2015-07-03 Holden Brien Vision Inst
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
WO2012102100A1 (ja) * 2011-01-26 2012-08-02 雪印メグミルク株式会社 感覚改善剤
CA2826192A1 (en) 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN109260465A (zh) * 2012-11-14 2019-01-25 史密夫和内修公司 稳定的嗜热菌蛋白酶水凝胶
MX2015013244A (es) 2013-03-15 2016-04-15 Smith & Nephew Inc Pelicula soluble formadora de gel para suministrar agentes activos.
JP6275955B2 (ja) * 2013-04-25 2018-02-07 松尾 敏郎 塩化マグネシウムを摂取する人を除いた生物の細胞の活性化方法
CZ308554B6 (cs) * 2013-10-21 2020-11-25 Univerzita Tomáše Bati ve Zlíně Hydrogelová kosmetická nebo farmaceutická kompozice s účinnějším působením v ní obsažených biologicky aktivních látek z hlediska antimikrobiálních účinků
KR20170086019A (ko) 2014-09-24 2017-07-25 이스티튜토 프로필라티코 이 파르마씨유티코 칸디올리 & 씨. 에스.피.에이. 감염증 및 염증의 예방 및/또는 치료에 유용한 조성물
RU2658707C1 (ru) * 2016-12-28 2018-06-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ восстановления кожного покрова
US20200024329A1 (en) * 2018-07-17 2020-01-23 Bradley G. Thompson Methods for regulating endogenous production of lactoferrin and sub-peptides thereof
EP3845218A4 (en) * 2018-07-31 2022-05-04 Lemonex Inc. PHARMACEUTICAL COMPOSITION FOR WOUND HEALING
US20220016220A1 (en) * 2018-12-11 2022-01-20 Universita' Degli Studi Di Salerno Composition for the treatment of skin lesions
BE1027357B1 (nl) * 2019-06-12 2021-01-18 Vanlommel Maria Kristel Voedingssupplement voor versnelde genezing
CN110680949B (zh) * 2019-10-18 2021-06-29 中山大学 一种基于母乳的创伤敷料的制备方法和应用
UY39909A (es) * 2021-08-23 2023-03-31 Lactea Therapeutics Llc Composiciones de lactoferrina y métodos de uso
CN113576938B (zh) * 2021-08-26 2022-07-08 广东丸美生物技术股份有限公司 一种口腔护理组合物及其应用
US20240165297A1 (en) * 2022-08-19 2024-05-23 Philip Neil MacPherson Hydrogel delivery matrix
CN116421775A (zh) * 2023-04-21 2023-07-14 青岛优瑞达生物科技有限公司 一种乳铁蛋白凝胶敷料、制备方法和应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4788488A (en) * 1986-10-14 1988-11-29 Drexelbrook Controls, Inc. Continuous condition sensing system
US4783488A (en) * 1987-01-31 1988-11-08 Bausch & Lomb Incorporated Contact lens wetting solution
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US6100054A (en) 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5571691A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
WO1991010437A1 (en) * 1990-01-12 1991-07-25 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of enhancing wound healing and tissue repair
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US6066469A (en) 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
GB2248842A (en) 1990-10-16 1992-04-22 American Cyanamid Co Film-forming polymer compositions
EP0579830B1 (en) * 1990-11-13 1997-02-05 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal lesion
CA2110899C (en) 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
WO1993013216A1 (en) 1991-12-24 1993-07-08 The President And Fellows Of Harvard College Site-directed mutagenesis of dna
DE69322896T2 (de) * 1992-03-02 1999-05-27 Immuno Japan Inc., Tokio/Tokyo Verwendung von Proteinen der Transferrin/Lactoferrin-Familie zur Stimulation des Immunsystems
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
WO1993020826A1 (fr) * 1992-04-10 1993-10-28 Vsesojuzny Nauchno-Issledovatelsky Institut Meditsinskikh Polimerov Composition pharmaceutique
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5358706A (en) 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
JPH07196529A (ja) * 1993-12-29 1995-08-01 Morinaga Milk Ind Co Ltd 創傷治癒剤、化粧料および養毛剤
JPH09509165A (ja) 1994-02-16 1997-09-16 ファーミング ベスローテン フェンノートシャップ ミルクからのラクトフェリンの分離
JP3746081B2 (ja) 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
US5827874A (en) * 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
GB2321191B (en) 1997-01-17 2000-09-27 Johnson & Johnson Medical Peptides for use in wound treatment
AU6307698A (en) 1997-02-03 1998-08-25 Pharming Bv Useful properties of human lactoferrin and variants thereof
CN1262625A (zh) * 1997-04-10 2000-08-09 阿吉尼克斯股份有限公司 乳铁蛋白在治疗过敏原诱发疾病中的应用
JP3856908B2 (ja) * 1997-06-06 2006-12-13 田辺製薬株式会社 褥瘡及び／又は創傷治療剤
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
ES2384099T3 (es) 2001-06-13 2012-06-29 The University Of Sydney Proteína C para cicatrización de heridas
WO2003094952A1 (en) * 2002-05-10 2003-11-20 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
SI2298338T1 (sl) * 2002-09-16 2012-11-30 Agennix Inc Laktoferinski sestavki in postopki za zdravljenjekožnih ran
AU2003291206A1 (en) 2002-12-04 2004-06-23 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
EP1581243A4 (en) 2002-12-06 2008-01-02 Agennix Inc ORAL LACTOFERRIN FOR SEPSIS TREATMENT
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2003293500A1 (en) * 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
US7034126B2 (en) 2003-05-14 2006-04-25 Agennix, Inc. Lactoferrin in the treatment of diabetes mellitus
AU2004289170B2 (en) 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106139124A (zh) * 2006-07-03 2016-11-23 让-保罗·佩罗丹 抗菌剂组合物及其用途
CN103442592A (zh) * 2010-12-29 2013-12-11 Mjn美国控股有限责任公司 包含乳铁蛋白的营养组合物在刺激免疫细胞中的用途
CN107252090A (zh) * 2010-12-29 2017-10-17 Mjn 美国控股有限责任公司 包含乳铁蛋白的营养组合物在刺激免疫细胞中的用途
TWI629994B (zh) * 2010-12-29 2018-07-21 美強生營養品美國控股公司 包括乳鐵蛋白之營養組成物於刺激免疫細胞上之用途
CN107854737A (zh) * 2011-08-31 2018-03-30 凯希特许有限公司 减压治疗与清创系统以及方法
CN110075054A (zh) * 2019-06-06 2019-08-02 山东天源人乳库科技发展有限公司 一种来源于人乳的人源性生长因子修复制剂及其制备方法
CN116251224A (zh) * 2023-05-16 2023-06-13 江苏正大天创生物工程有限公司 一种乳铁蛋白凝胶敷料及其应用
CN116251224B (zh) * 2023-05-16 2023-09-12 江苏正大天创生物工程有限公司 一种乳铁蛋白凝胶敷料及其应用

Also Published As

Publication number Publication date
DE60335997D1 (de) 2011-03-24
AU2009225309B2 (en) 2012-06-14
WO2004024180A1 (en) 2004-03-25
US20040142037A1 (en) 2004-07-22
AU2003270690A1 (en) 2004-04-30
ATE497778T1 (de) 2011-02-15
EP2298338A1 (en) 2011-03-23
JP2006503044A (ja) 2006-01-26
AU2009225309A1 (en) 2009-11-05
EP1545587B1 (en) 2011-02-09
AU2003270690B2 (en) 2009-07-30
DK1545587T3 (da) 2011-05-09
JP4516844B2 (ja) 2010-08-04
CA2499014A1 (en) 2004-03-25
SI2298338T1 (sl) 2012-11-30
DK2298338T3 (da) 2012-09-24
ES2358645T3 (es) 2011-05-12
EP1545587A4 (en) 2009-06-17
SI1545587T1 (sl) 2011-06-30
US8030272B2 (en) 2011-10-04
US7524814B2 (en) 2009-04-28
EP2298338B1 (en) 2012-08-22
US8247373B2 (en) 2012-08-21
US20120010150A1 (en) 2012-01-12
EP1545587A1 (en) 2005-06-29
US20090253627A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
CN1694720A (zh) 乳铁蛋白组合物和创伤治疗的方法
JP4809352B2 (ja) 線維芽細胞成長因子２１の突然変異タンパク質
CN1248734C (zh) 用于伤口愈合的基质蛋白组合物
CN1158068C (zh) 用于缓释蛋白质的多元醇/油悬浮剂
CN101056618A (zh) 眼用组合物和治疗眼睛的方法
EP2938626A1 (en) Self-assembled ultrashort peptides hydrogels for wound healing, skin care and cosmetics applications
CN1309666A (zh) 葡糖醛酸葡聚糖的聚合物复合物
CN1283997A (zh) 角质形成细胞生长因子－2制剂
JPWO2016093326A1 (ja) 血管新生病の免疫療法
CN1089505A (zh) 非免疫原性蛋白性物质和组分的新药物用途
CN1913917A (zh) 凝血酶肽衍生物的药物组合物
WO2007022537A2 (en) Use of lactoferrin as a chemokine and a chemotactic modulator
HK1085126A (en) Lactoferrin compositions and methods of wound treatment
JP7774276B2 (ja) ペプチドを含む組成物及びその用途
US20230082131A1 (en) Compositions including amelogenin and uses thereof
KR20130055665A (ko) 소 과립구 콜로니 자극 인자 및 그의 변이체를 위한 제제
CN1917904A (zh) 有机硅化合物用于约束结缔受损组织的用途
CN1872337A (zh) 水蛭素鼻腔给药制剂及其用途
CN1769299A (zh) 一种新型融合蛋白的制造及应用
HK1074770B (en) Enamel matrix protein compositions for modulating immune response
HK1074770A1 (zh) 用於调节免疫反应的釉质基质蛋白组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1085126

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20051109

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1085126

Country of ref document: HK